Roth MKM analyst Boobalan Pachaiyappan initiated coverage of Verona Pharma (VRNA) with a Buy rating and $68 price target The firm says its ...
Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...
Verona Pharma (NASDAQ:VRNA – Get Free Report) had its price target raised by investment analysts at Wells Fargo & Company ...
Zacks.com on MSN1h
Verona Pharma (VRNA) Upgraded to Buy: What Does It Mean for the Stock?Verona Pharma PLC American Depositary Share (VRNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...
As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.
With over $410 million in financing; to advance portfolio of next-gen oral and injectable treatments with first- or ...
Eurovetrocap’s founding family will retain a minority stake in the company, and the existing management team will remain in ...
What does Nifty Pharma represent? Tracks the performance of pharmaceutical companies in India, comprising leading pharmaceutical stocks listed on the National Stock Exchange (NSE), reflecting trends ...
Sun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 4,38,202.54 Crore) operating in Pharmaceuticals sector. Sun Pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback